| June 30, | ||||||||
| 2017 | 2016 | |||||||
| Deferred Tax Assets: | ||||||||
| Net operating loss carry-forwards | $ | 74,330 | $ | 68,914 | ||||
| Research credits | 4,168 | 3,891 | ||||||
| Fixed asset depreciation | — | 48 | ||||||
| Stock compensation | 570 | 393 | ||||||
| Deferred revenue | 296 | 151 | ||||||
| Other | 1,144 | 1,123 | ||||||
| Total deferred tax assets | 80,508 | 74,520 | ||||||
| Valuation A llowance | (80,481 | ) | (74,520 | ) | ||||
| Deferred Tax Liabilities: | ||||||||
| Fixed asset depreciation | (27 | ) | — | |||||
| Net Deferred Tax Assets | $ | — | $ | — | ||||
| Fiscal Year Ended June 30, | ||||||||||||
| 2017 | 2016 | 2015 | ||||||||||
| Tax benefit at U.S. statutory rate | $ | (5,855 | ) | $ | (5,449 | ) | $ | (6,520 | ) | |||
| Loss for which no tax benefit is currently recognizable | 5,052 | 5,292 | 6,341 | |||||||||
| Loss on issuance of convertible preferred stock Series B and related warrants, and remeasurement of common stock warrant liability | 712 | — | — | |||||||||
| Refundable research credits | (160 | ) | — | — | ||||||||
| Stock-based compensation | 141 | 140 | 160 | |||||||||
| Prior year adjustments | 98 | — | — | |||||||||
| Other, net | 12 | 17 | 19 | |||||||||
| $ | — | $ | — | $ | — | |||||||
| Amount | ||||
| Balance at June 30, 2014 | $ | 1,013 | ||
| Additions based on tax positions related to prior years | 26 | |||
| Additions based on tax positions related to current year | 82 | |||
| Balance at June 30, 2015 | 1,121 | |||
| Additions based on tax positions related to prior year | 56 | |||
| Additions based on tax positions related to current year | 79 | |||
| Balance at June 30, 2016 | 1,256 | |||
| Additions based on tax positions related to prior years | — | |||
| Additions based on tax positions related to current year | 84 | |||
| Balance at June 30, 2017 | $ | 1,340 | ||